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CCR6 Is Required for Epidermal Trafficking of
cd-T Cells in an IL-23-Induced Model of
Psoriasiform Dermatitis
Tomotaka Mabuchi1, Tej Pratap Singh2, Tomonori Takekoshi1, Guang-fu Jia1, Xuesong Wu1,
Mandy C. Kao1, Ido Weiss2, Joshua M. Farber2 and Sam T. Hwang1
A subset of CC chemokine receptor-6þ (CCR6þ ), gd-low (GDL) T cells that express Th17 cytokines in mouse skin
participates in IL-23-induced psoriasiform dermatitis. We used CCR6-deficient (knockout, KO) and wild-type
(WT) mice to analyze skin trafficking patterns of GDL T cells and function-blocking mAbs to determine the role
of CCR6 in IL-23-mediated dermatitis. Herein, CCL20 was highly upregulated in IL-23-injected WTmouse ear skin
as early as 24 hours after initial treatment, and large numbers of CCR6þ cells were observed in the epidermis of
IL-23-injected WT mice. Anti-CCL20 mAbs reduced psoriasiform dermatitis and blocked recruitment of GDL T
cells to the epidermis. In CCR6 KO mice, GDL T cells failed to accumulate in the epidermis after IL-23 treatment,
but the total numbers of GDL T cells in the dermis of WT and CCR6 KO mice were equivalent. There was an
B70% reduction in the proportion of IL-22þ GDL T cells in the dermis of CCR6 KO mice (vs. WT mice),
suggesting that effector function and epidermal recruitment of GDLT cells are impaired in CCR6-deficient mice.
Thus, these data show that CCR6 regulates epidermal trafficking of gd-T-cell subsets in the skin and suggest the
potential of CCR6 as a therapeutic target for psoriasis.
Journal of Investigative Dermatology (2013) 133, 164–171; doi:10.1038/jid.2012.260; published online 16 August 2012
INTRODUCTION
The immunopathogenesis of psoriasis has been revealed in
much greater depth and complexity as new data suggest that
the Th17 signaling pathway has key roles in the development
of psoriasis (Fitch et al., 2007). IL-23, a key upstream factor in
the Th17 pathway, is an essential cytokine for the main-
tenance of Th17 cells, and therapeutic agents targeting the
shared p40 component of IL-23 have shown remarkable
clinical efficacy in psoriasis (Leonardi et al., 2008). Current
models suggest that IL-23 produced by dendritic cells act to
sustain dermal CC chemokine receptor-6 (CCR6)-expressing
Th17 cells, which then produce IL-22 as a major downstream
effector molecule that mediates epidermal hyperplasia
(Nograles et al., 2010).
It is noteworthy that CCR6 itself is not simply a marker for
Th17 cells, but several reports suggest that CCR6 has
functional relevance to the trafficking and/or function of
T-cell subsets associated with the Th17 pathway. For
example, anti-murine CCR6 antibodies have shown efficacy
in ameliorating Th17-mediated autoimmune disease models
of experimental autoimmune encephalomyelitis (Liston et al.,
2009) and collagen-induced arthritis (Hirota et al., 2007), but
their benefit in psoriasiform skin models has never been
shown. We have shown, however, that mice deficient in
CCR6 fail to develop the psoriasiform dermatitis that is
observed in wild-type (WT) mice after injection of IL-23
(Hedrick et al., 2009). Interestingly, there are also reports that
CCR6 may be expressed by regulatory T cells and, thus,
functions in some situations, including chronic encephalo-
myelitis, to help dampen the immune response (Elhofy et al.,
2009; Villares et al., 2009).
Recent data reveal that specific subsets of gd-T cells in
mice are present in the dermis (Gray et al., 2011), express
CCR6 and the IL-23 receptor, and respond to IL-23 and IL-1b
by secreting IL-17 and IL-22 (Haas et al., 2009; Sutton et al.,
2009; Cua and Tato, 2010). In human studies, Laggner et al.
(2011) have described a CCR6þ , Vg9Vd2 T-cell subset in
peripheral blood, which is decreased in the blood, but
increased in the skin, of psoriatic patients. In addition, these
authors showed by immunofluorescence microscopy that
Vd2 receptor–positive T cells are present in large numbers in
psoriatic, but not healthy, skin (Laggner et al., 2011).
Drivers of Th17 inflammation, such as IL-23, and Th17
cytokines, such as IL-22, has critical roles in psoriasis through
their effects in maintaining Th17 cells and stimulat-
ing epidermal hyperplasia, respectively (Fitch et al., 2007;
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Zheng et al., 2007). Ustekinumab, a mAb that targets the p40
subunit of IL-23, has been shown to be very effective in
ameliorating human psoriasis (Leonardi et al., 2008). We
(Hedrick et al., 2009; Mabuchi et al., 2011) and others (Chan
et al., 2006; Zheng et al., 2007) have shown that injection of
IL-23 in murine skin results in a psoriasiform dermatitis with
striking similarity to human psoriasis, including epidermal
hyperplasia, parakeratosis, and neutrophils in the cornified
layer, and dense Th17-predominant inflammatory infiltrates.
In the IL-23 injection model, we have previously observed that
both CD4þ T cells and CD11cþ dendritic cells, but neither
macrophages nor neutrophils, are increased in the dermis of
either WT or CCR6-deficient mice (Hedrick et al., 2009).
We have demonstrated that IL-23 injection in WT mouse
skin results in the epidermal recruitment of CCR6þ , IL-23
receptorþ , and Vg3 gd-low-intermediate T cells (GDL T
cells) that express high levels of IL-17 and IL-22 (Mabuchi
et al., 2011). These gd-T cells appear to be required to
maximize ear swelling in the initial response to injected IL-23,
as gd-T cell–deficient mice had delayed increases in ear
swelling compared with WT mice (Mabuchi et al., 2011). A
population of gd-T cells with a similar CCR6þ phenotype has
also been described as highly motile and distinct in several
important ways from dendritic epidermal T cells (DETCs) (Gray
et al., 2011), and dermal gd-T cells have now been reported to
produce IL-22 and IL-17 in imiquimod-induced models of
psoriasiform dermatitis (Cai et al., 2011; Van Belle et al.,
2012). It is conceivable that, under the appropriate inflamma-
tory conditions, these dermal GDL T cells migrate in large
numbers to the epidermis, where the release of IL-22 would
very effectively stimulate epidermal hyperplasia.
Although it was clear from our prior work that epidermal
GDL T cells expressed CCR6, whereas skin resident Vg3þ
(also called Vg5, depending on the nomenclature) gd-T cells
known as dendritic epidermal T cells (DETCs) did not
(Mabuchi et al., 2011), the functional role of CCR6 and its
ligand CCL20 in trafficking of GDL T cells to epidermis under
inflammatory conditions is uncertain. Moreover, it is also
clear that epidermal cells, particularly keratinocytes, can
synthesize the CCR6 ligand, CCL20, when triggered by
inflammatory stimuli (Schutyser et al., 2003). CCL20 protein
was immunohistologically apparent after 15 days of repeated
injections of IL-23 in murine skin (Hedrick et al., 2009), but
the kinetics of CCL20 production in the skin in this model has
not been fully explored. Herein, to determine whether CCL20
and its receptor, CCR6, were required for trafficking of GDL T
cells to epidermis, we blocked CCL20 with mAbs in our IL-23
injection model and showed that trafficking of GDL T cells to
the epidermis was markedly reduced. Of therapeutic note,
anti-CCL20 mAbs also reduced dermal inflammation. In-
triguingly, we observed a marked decrease in the production
of IL-22 in GDL T cells from the skin of CCR6 knockout (KO)
mice following IL-23 stimulation, suggesting that CCR6 may
be involved in maximally triggering the production of IL-22.
These data reveal mechanistic insights regarding the chemo-
kine regulation of trafficking of unconventional gd-T-cell
subsets in skin and suggest the potential relevance of CCR6/
CCL20 as a therapeutic target for psoriasis.
RESULTS
CCL20 expression in mouse epidermis is rapidly upregulated
after IL-23 injection
Harper et al. (2009) have shown that Th17 cytokines (IL-17A,
IL-22, and tumor necrosis factor-a) upregulate CCL20 in
murine skin following local injection, and our previous study
indicated that CCL20 could be detected in mouse epidermis
following nearly 2 weeks of treatment with IL-23 (Hedrick
et al., 2009), but earlier time-point analysis was not
performed. As we detected CCR6 expression in GDL T cells,
we asked whether CCL20 was upregulated at early time
points following IL-23 injection, presuming that CCL20 may
be a major chemoattractant for GDL T-cell migration to the
epidermis. As early as 24 hours following the initiation of
IL-23 treatment, CCL20 expression was highly upregulated in
murine epidermis (compared with phosphate-buffered saline
(PBS)-treated control skin) and was maintained at similar
levels throughout the duration of the experiment (Figure 1).
Thus, CCL20 is rapidly produced by keratinocytes in vivo in
response to IL-23, potentially serving as an epidermal
chemoattractant for GDL T-cell migration to the epidermis.
Neutralizing anti-CCL20 mAbs reduce psoriasis-like
inflammation and trafficking of IL-22-producing, CCR6-
expressing GDL T cells into the epidermis in response to IL-23
injection
To ascertain whether CCL20 is required for the entry of GDL
T cells into the epidermis during IL-23 injection–induced
epidermal inflammation, we mixed IL-23 with neutralizing
anti-CCL20 mAbs or isotype control and injected this mixture
into the skin of mice as we have previously described
(Mabuchi et al., 2012). Because ear swelling is a useful
measure of dermal inflammation (edema) in this model, we
measured ear thickness before each injection. Whereas mice
injected with the isotype control mAb and IL-23 mixture
displayed the usual ear swelling over 5 days, PBS-injected
ears failed to show any significant increase in ear swelling
(Figure 2a). Ears injected with neutralizing anti-CCL20 mAb
plus IL-23, however, showed significant reductions in ear
swelling compared with isotype control and IL-23-injected
Day 1
PBS
IL-23
CCL20 / DAPI
Day 3 Day 5
Figure 1. CCL20 expression in mouse epidermis is upregulated within
24 hours of IL-23 injection. IL-23 was injected into the ears of wild-type mice
at days 0, 2, and 4. Mice were killed on the indicated days and ears were
stained with anti-CCL20 antibody (red) and 46-diamidino-2-phenyl indole
(nuclear counterstain in blue). Isotype control staining showed no epidermal
staining with either IL-23 or phosphate-buffered saline-injected ears (data not
shown). Bar¼ 50 mm.
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ears (Figure 2a). A significant reduction in mean epidermal
thickness was also noted in anti-CCL20 mAb plus IL-23-
injected ears compared with isotype controls (Figure 2b).
Hematoxylin and eosin–stained sections from WT ears
injected with isotype control mixed with IL-23 on day 5
revealed psoriasis-like changes, namely parakeratosis, epi-
dermal hyperplasia, and mixed mononuclear inflammatory
infiltrate (Figure 2c). By contrast, mice treated with neutraliz-
ing anti-CCL20 mAb and IL-23 showed minimal paraker-
atosis, decreased immune cells infiltration, and reduced
epidermal hyperplasia (Figure 2c). Thus, anti-CCL20 mAb
treatment markedly reduces the major epidermal and dermal
inflammatory effects of IL-23 treatment.
Following treatment with isotype control mAb plus IL-23,
neutralizing anti-CCL20 mAb plus IL-23, or PBS injection for
5 days, both epidermal and dermal cell suspensions were
prepared for flow cytometry and reverse transcriptase–PCR.
Pooled epidermal (Figure 3a) and dermal (Figure 3b) cell
suspensions were stained with mAbs against gd-TCR. As
expected, the number of GDL T cells was increased in the
epidermis in isotype control mAbs plus IL-23 injections
compared with PBS-injected ears (Figure 3a). However, the
accumulation of GDL T cells in the epidermis treated with
neutralizing anti-CCL20 antibodies and IL-23 mixture was
lower (76% reduction in Figure 3a with another experiment
showing 54% reduction) than that of epidermis treated with
isotype control plus IL-23, approaching levels seen with PBS
injection alone (Figure 3a). On the other hand, the numbers
of GDL T cells in the dermis treated with isotype control
mAbs plus IL-23 and neutralizing anti-CCL20 mAbs plus
IL-23 were both decreased compared with GDL T cells found
in PBS-injected ears (Figure 3b). Reverse transcriptase–PCR
analysis revealed that both epidermal (Figure 3c) and dermal
(Figure 3d) cells from ears treated with neutralizing anti-
CCL20 mAbs plus IL-23 showed a significant reduction in the
expression of IL-22 and CCR6 mRNA when compared with
isotype control plus IL-23-injected ears. Thus, anti-CCL20
mAbs block accumulation of GDL T cells in the epidermis
and reduce the expression of IL-22 mRNA in both the dermal
and epidermal compartments.
Trafficking of GDL cells to the epidermis correlates with the
entry of CCR6þ cells into the epidermis
To determine whether CCR6 is required for the entry of GDL
T cells to the epidermis during the IL-23 injection protocol,
frozen sections of whole mouse ears were stained with mAbs
against CCR6 and laminin 332 (as a marker for the basement
membrane). We observed increased numbers of CCR6þ cells
in the epidermis of IL-23-injected, but not PBS-injected, skin
localized by the three-dimensional projections acquired
using immunofluorescence confocal microscopy (Figure 4a
and b). We had previously observed CCR6þ cells in IL-23-
treated skin by conventional sections (Mabuchi et al., 2011),
but the three-dimensional projections allowed us to better
appreciate the presence of large numbers of CCR6þ cells that
accumulated in IL-23-treated skin. Close inspection at the
level of the basement membrane (revealed by anti-laminin
332 antibodies, red) showed many CCR6þ cells at (arrow
head), immediately adjacent to (double arrow heads), or
above (arrow) the basement membrane, suggesting that
these cells may have been moving into the epidermis
(Figure 4a and b). To show CCR6þ GDL T cells in
relationship to gd-high resident DETCs, which express low
levels of CCR6 (Mabuchi et al., 2011), we double stained skin
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Figure 2. Neutralizing anti-CCL20 mAbs inhibit the ear swelling in response to IL-23 injection. (a) Wild-type mice were injected with neutralizing anti-CCL20
mAb, isotype control, or phosphate-buffered saline (PBS) in the ear skin with subsequent measurement of ear thickness throughout the treatment period.
*Po0.01 versus all other groups. **Po0.01 versus PBS-injected groups. These experiments were repeated four times with similar results. (b) At day 5 following
treatment with neutralizing anti-CCL20 mAb, isotype control, or PBS injection, ears were harvested and (c) the epidermal thickness was measured (at points
indicated by white rectangles) in paraffin-embedded, hematoxylin and eosin–stained tissues using Infinity Analyze analysis software. Similar results were
obtained in two independent experiments. *Po0.01. Bar¼ 100mm.
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of IL-23-treated mice with differentially labeled mAbs to
CCR6 (green) and the gd-TCR (red). Whereas red, gd-high
cells were present in both PBS- and IL-23-treated skin (Figure
4c and data not shown), green, CCR6þ cells were only
abundant in IL-23-treated skin (Figure 4c), clearly showing
that the CCR6þ population of GDL T cells was distinct from
DETCs in the epidermis.
CCR6 is required for IL-22 production by GDL T cells and their
trafficking to epidermis
In our prior work, we showed that CCR6 was critical for the
development of a psoriasiform dermatitis following IL-23
injection, as CCR6-deficient mice were unable to develop the
inflammatory and hyperplastic phenotype of WT mice after
exposure to IL-23 (Hedrick et al., 2009). However, in that
work we were surprised to note that the numbers of Th17-
and IL-22-producing cells were similar in the IL-23-treated
skin of WT and CCR6 KO mice. At that time, we did not
determine whether unconventional T-cell populations (i.e.,
gd-TCR T cells) were affected in numbers, especially in the
epidermis, in CCR6-deficient mice. Thus, we subjected CCR6
KO mice to our IL-23 skin injection protocol. Following
treatment with IL-23 or PBS injection for 5 days, both
epidermal and dermal cell suspensions were stained with
mAbs against CD3, gd-TCR, and IL-22 for flow cytometry.
Following IL-23 injection, the total numbers of GDL T cells
in the epidermis (as expected) were increased in the IL-23-
injected WT ears compared with PBS-injected WT ears. The
accumulation of GDL T cells, however, in the IL-23-treated
CCR6 KO epidermis was similar to that observed in PBS-
treated epidermis (Figure 5a, left). Similarly, CCR6 KO mice
failed to accumulate CD3þ GDL T cells in the epidermis
(Figure 5b, left) and IL-22þ GDL T cells (Figure 5c, left) in the
epidermis following IL-23 injection. Whereas IL-23 injection
resulted in a significant increase in the proportion of IL-22þ
GDL T cells in the epidermis in WT mice (Po0.05), it did not
significantly increase this population of cells in CCR6 KO
mice (P¼0.5). This phenomenon was also observed in the
dermis (Figure 5c), suggesting that the CCR6 may be
necessary not only for epidermal trafficking but also for the
activation of GDL T cells such that they produce IL-22 at high
levels. Note that there were no significant differences
between PBS- and IL-23-injected mouse ears in the total
numbers of GDL T cells in the dermis of either WT or CCR6
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KO mice (Figure 5a, right). Thus, CCR6 is required for both
entry of GDL T cells into the epidermis following IL-23
stimulation and for maximal production of IL-22 by GDL T
cells, particularly in the dermis.
DISCUSSION
Herein, we have shown in several different ways that CCR6
may be critical for the trafficking GDL T cells to the
epidermis. First, anti-CCL20 mAbs block the migration of
GDL T cells to the epidermis. Moreover, these neutralizing
antibodies ameliorate the epidermal hyperplasia and dermal
inflammation observed when IL-23 is injected into WT
mouse skin. Second, GDL T cells fail to accumulate in the
epidermis of IL-23-treated CCR6 KO mice, strongly suggest-
ing that CCR6 may be required for effective trafficking to the
epidermis under these proinflammatory conditions. Confocal
microscopy shows that CCR6þ cells clearly accumulate in
murine epidermis following IL-23 injection where the
proximity of these cells to the basement membrane (Figure 4)
suggests movement of CCR6þ cells from the dermis into the
epidermis as a result of IL-23 injection.
In other inflammatory settings, unconventional gd-T cells
have been shown to be capable of producing high levels of IL-
22 and other key Th17 cytokines (Haas et al., 2009; Sutton
et al., 2009; Cua and Tato, 2010), but their role in skin is only
just beginning to be explored. Our prior studies (Mabuchi
et al., 2011) and those described herein revealed that a
population of CCR6þ , Vg3/Vg5 gd-T cells (with low-
intermediate expression of the gd-receptor), hence the name
GDL T cells, accumulated in murine epidermis upon exposure
to IL-23. GDL T cells that accumulate in inflamed skin are
distinct from resident DETCs that express Vg3(5) and which
are constitutively present in resting mouse skin (Gray et al.,
2011; Mabuchi et al., 2011). As thoroughly discussed by
others, DETCs serve distinct roles in immune regulation and
cancer surveillance in the mouse (Girardi, 2006). In contrast
to murine epidermis in which large numbers of DETCs are
present in the epidermis, human epidermis appears to lack an
equivalent cell population (Girardi, 2006), and thus the
immunological roles of DETCs in humans are unclear.
However, recent data indicate that Vg9Vd2þ T cells do
accumulate in great numbers in the skin of patients with
active psoriatic lesions (Laggner et al., 2011).
Recent human data support the potential relevance of
CCR6þ and gd-T cells in psoriasis. First, Kagami et al. (2010)
have described increases (that normalized during anti-tumor
necrosis factor-a therapy) in IL-17Aþ , CCR6þ T cells in the
blood of psoriatic patients. Interestingly, Laggner et al. found
decreases in CCR6þ , gd-T cells in the blood of psoriatic
patients, whereas large increases in the numbers of these cells
were noted in the skin of patients with active disease,
suggesting possible movement of gd-T cells into the skin.
The large increases in CCR6þ T cells in the blood may reflect
the ability of conventional CCR6þ ab-T cells to expand in
number in the peripheral blood, whereas CCR6þ gd-T cells
may alter their trafficking patterns (without necessarily
expanding in numbers) during active disease.
Thus, we would propose that inflammatory triggers such as
IL-23 induce sufficient CCL20 in the epidermis to begin
attracting large numbers of GDL T cells that then produce IL-
22, IL-17, and possibly other factors that influence epidermal
hyperplasia and dermal edema. As shown in Figure 1, CCL20
a bIL-23 PBS
IL-23c
γδ-TCR / CCR6
CCR6 / Laminin 332
Figure 4. Immunofluorescence staining for CC chemokine receptor-6 (CCR6) expression following IL-23 injection. Following (a) IL-23 or (b) phosphate-
buffered saline (PBS) injection for 6 days, mice were killed and ears were stained with anti-CCR6 mAbs (green) and anti-Laminin 332 mAbs (basement
membrane in red), and the three-dimensional images were acquired using a confocal microscope. The figure shows the perspective from the dermis toward the
epidermis. The width of basement membrane in red shows the depth of the sections. Larger numbers of CCR6-expressing cells in the epidermis (above the
basement membrane) were revealed in IL-23-injected, but not PBS-injected, mice. (a) CCR6-expressing cells at (arrowhead), immediately adjacent to (double
arrowheads), or above (arrow) the basement membrane in the dashed rectangular area marked in the upper figure are shown at higher magnification below.
Isotype control staining showed no staining with either IL-23- or PBS-injected ears (data not shown). Bar¼ 10mm. (c) IL-23-treated skin sections were stained
with labeled mAbs against CCR6 (green) and the gd-TCR (red). Images were acquired by confocal microscopy at the level of the epidermis ( 63 objective, scale
bar as indicated). Similar results were obtained in three independent experiments.
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is rapidly upregulated in murine epidermis upon injection of
skin with IL-23. In our prior publication (Hedrick et al.,
2009), we observed that CCR6 KO (vs. WT) mice showed
greatly diminished expression of IL-22 mRNA at both early (5
days) and late (15 days) time points during the IL-23 injection
protocol. It is noteworthy that IL-17A and IL-17F expression
was markedly reduced in CCR6 KO mice only at the early,
but not at late, time points, suggesting that IL-22 expression
correlated more closely with dermal edema (and psoriatic
phenotype) than did IL-17A/F expression. These data
substantiate recent results from Rizzo et al. (2011) showing
that, although IL-17A has a role in the IL-23 injection model,
the role of IL-22 seems to be greater.
The potential of CCR6 or its ligand, CCL20, as a
therapeutic target for psoriasis has been postulated since
Homey et al. (2000) first showed high expression of CCL20
and CCR6 in psoriatic skin more than a decade ago and has
been reviewed recently at greater depth (Hedrick et al., 2010;
Mabuchi et al., 2012). Indeed, our current studies confirm
that targeting the chemokine ligand, CCL20, with neutraliz-
ing antibodies can effectively block the development of
epidermal hyperplasia and dermal inflammation, although
the degree of inhibition is not quite as striking as that
observed when CCR6-deficient mice were treated with IL-23
(Hedrick et al., 2009). Compared with the response seen with
anti-CCL20 mAb, the near complete lack of response in
CCR6 KO mice might be anticipated because of the total
absence of the CCR6 receptor. A CCL20-directed intervention
for psoriasiform dermatitis has not to our knowledge been
previously reported. Others have targeted CCR6 with mAbs
in animal models of autoimmune disease, specifically
encephalomyelitis (Liston et al., 2009) and collagen-induced
arthritis (Hirota et al., 2007), suggesting that targeting CCL20
may also be a viable strategy for diseases other than psoriasis.
Interestingly, gd-T cells from CCR6 KO mice not only
failed to accumulate in the epidermis after IL-23 treatment,
but even those that did enter the epidermis expressed low
amounts of IL-22 compared with WT GDL T cells (Figure 5).
This suggested that not only recruitment but also function of
gd-T cells may be impacted by the lack of CCR6. There are
several possible explanations. It is well known that chemo-
kine receptors activate PI3K and its downstream effector to
impact survival and activation pathways (Murakami et al.,
2003). Thus, we hypothesize that CCR6 has a role in
coactivating GDL T cells. Alternatively, the lack of other
cells in the dermis, possibly CD11c dendritic cells (that
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Figure 5. CC chemokine receptor-6 (CCR6) knockout (KO) mice fail to accumulate IL-22þ , cd-low (GDL) T cells in response to IL-23 injection. Following
IL-23 injection for 6 days, both wild-type (WT) and CCR6 KO mice were killed. Both epidermal and dermal cell suspensions were analyzed by flow cytometry
with gd-TCR, CD3, and IL-22 mAbs. (a) Total numbers of GDL T cells per phosphate-buffered saline (PBS)- or IL-23-injected ear of WT and CCR6 KO mice
were counted. (b) The percentages of CD3þ GDL T cells and (c) IL-22þ GDL T cells were calculated. *Po0.01 versus all other groups. **Po0.05 versus
all other groups. Each treatment group consisted of four ears. All P-values were calculated using a two-sided Student’s t-test. In panel c (epidermis), P-values are
provided for comparisons between PBS and IL-23 treatment in WT and CCR6 KO mice. Similar results were obtained in two independent experiments.
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express IL-23 and other cytokines) that we observed to be
substantially decreased in the dermis of IL-23-treated CCR6
KO mice (Hedrick et al., 2009), might have an impact on the
ability of GDL T cells to become activated.
Combined with our prior study (Mabuchi et al., 2011), our
current results now firmly implicate recruited Vg3/Vg5 GDL
T cells as important participants in IL-23-mediated psoriasi-
form dermatitis. Although we acknowledge that human
psoriasis is likely to be driven not solely by IL-23, but
possibly by other cytokines such as IL-21 (Caruso et al.,
2009), the therapeutic efficacy of ustekinumab (targeting the
shared p40 subunit of IL-23 and IL12) (Leonardi et al., 2008)
coupled with clinical data correlating the expression of Th17
cytokines with efficacy of anti-tumor necrosis factor-a
antibodies (Zaba et al., 2009) suggests that the IL-23 injection
model may be a useful preclinical platform for testing agents
that might have efficacy in human psoriasis. Because other
chemokine receptors (e.g., CXCR4 and CCR5) have been
successfully targeted with small molecule inhibitors, our data
suggest that a search for small molecule antagonists of CCR6
may be of value in the treatment of psoriasis and other
autoimmune disorders.
MATERIALS AND METHODS
Mice
C57BL/6J WT mice were purchased from The Jackson Laboratory
(Bar Harbor, ME). Both C57BL/6 CCR6 KO mice and littermate
control WT mice used in Figure 5 were generated and housed at the
National Institutes of Health as described (Hedrick et al., 2009). All
mice were used at 8–12 weeks of age. Animal protocols were
approved by the Animal Care and Use Committees both at the
Medical College of Wisconsin and the National Institute of Allergy
and Infectious Diseases, National Institutes of Health.
Intradermal cytokine and neutralizing anti-CCL20 antibody
injections
We administered intradermal injection of 20 ml PBS containing
500 ng recombinant mouse IL-23 (BioLegend, San Diego, CA) or
20 ml PBS alone into both ears of anesthetized mice using a 28-gauge
needle every other day for 6 days as described (Mabuchi et al.,
2011). In the same way, we also administered intradermal injection
of 20 ml PBS containing 10 mg monoclonal anti-mouse CCL20/
MIP3a antibody (R&D Systems, Minneapolis, MN) mixed with
500 ng recombinant mouse IL-23, 20 ml PBS containing 10 mg rat
IgG1 isotype control (R&D Systems) mixed with 500 ng recombinant
mouse IL-23, or 20 ml PBS alone. Ear thickness was measured before
every injection as described (Mabuchi et al., 2011).
Processing of epidermal and dermal cells from mouse ears
After recovery of mouse ears, skin sheets were separated from
cartilage with forceps and incubated in PBS containing 0.5% trypsin
(US Biochemical, Cleveland, OH) for 40minutes at 37 1C with
dermal side down to separate epidermal sheets from dermal sheets.
To obtain cell suspensions, epidermal sheets were treated in DMEM
(Invitrogen, Grand Island, NY) containing 0.05% DNase I (Sigma-
Aldrich, St Louis, MO) and 10% fetal bovine serum as described
(Salgado et al., 1999). Dermal sheets were incubated in 15ml RPMI
Medium 1640 (Invitrogen) containing 40mg collagenase D (Roche,
Indianapolis, IN), 0.01% DNase I, and 20% fetal bovine serum for
45minutes at 37 1C as described (Szabo et al., 1998). Cells were then
filtered through a 70-mm nylon mesh and washed before use.
Histopathological analysis and immunofluorescence
microscopy
Frozen 5-mm sections of whole mouse ears were stained with hema-
toxylin and eosin. Images were acquired using an INFINITY3-1C
digital camera (Lumenera, Ottawa, ON, Canada) attached to a Carl
Zeiss microscope and INFINITY ANALYZE version 5.0.3 software
(Lumenera). Epidermal thickness was measured at four different points
on the image using INFINITY ANALYZE version 5.0.3 software.
Staining for CCR6, gd-TCR (BD Biosciences, San Jose, CA), and
Laminin 332 was done using frozen, 8-mm sections of whole mouse
ears. Sections were air-dried after 20minutes of fixation in cold
acetone, blocked for 1 hour at room temperature with 5% goat
serum, Fc-blocker (2.4G2, Bio X Cell, West Lebanon, NH), and goat
anti-rabbit IgG-HRP (Santa Cruz Biotechnology, Santa Cruz, CA) in
PBS containing 3% skim milk. After washing in PBS, tissue sections
were incubated with anti-mouse CCR6 mAb or rat IgG (R&D
Systems) overnight at 4 1C. After washing in PBS, the sections were
incubated with anti-laminin 332 antibody (Lazarova et al., 1996) or
rabbit IgG (R&D Systems) overnight at 4 1C. After washing in PBS,
the sections were incubated for 30minutes at room temperature with
Alexa-568-conjugated goat anti-rabbit IgG and Alexa-488-conju-
gated goat anti-rat IgG (Invitrogen), then washed in PBS and
mounted using ProLong Gold anti-fade reagent with 46-diamidino-
2-phenyl indole nuclear stain (Invitrogen). Images were acquired
using the Carl Zeiss LSM510 confocal microscope with axio-
observer microscope and LSM510 version 4.2 software.
Staining for CCL20 was done using frozen 8-mm sections of
whole mouse ears. Sections were air-dried after 10minutes of
fixation in cold acetone and blocked for 1 hour at room temperature
with 5% donkey serum, Fc-blocker, and donkey anti-goat IgG-HRP
(Santa Cruz Biotechnology) in PBS containing 3% skim milk. After
washing in PBS, the sections were incubated with mouse CCL20/
MIP-3a Affinity-Purified Polyclonal antibody or normal goat IgG
(R&D Systems) overnight at 4 1C. After washing in PBS, tissue
sections were incubated for 30minutes at room temperature with
Alexa-568-conjugated donkey anti-goat IgG (Invitrogen), then
washed in PBS and mounted using ProLong Gold anti-fade reagent
with 46-diamidino-2-phenyl indole nuclear stain. Images were
acquired using an INFINITY3-1C digital camera attached to a Carl
Zeiss microscope and INFINITY ANALYZE version 5.0.3 software.
Flow cytometry
mAbs against mouse gd-TCR (catalog # 553177), IL-22, and CCR6
were purchased from BD Biosciences, BioLegend, and R&D Systems,
respectively. Intracellular staining for IL-22 was performed after
incubating cells for 2 hours with GolgiStop (BD Biosciences). Cells
were then fixed and permeabilized using the BD Cytofix/Cytoperm
Plus Kit (BD Biosciences). Flow cytometric data were analyzed using
FlowJo version 7.5.5 software (Tree Star, Ashland, OR).
Real-time PCR
Extraction of RNA and subsequent analysis of mRNA expression of
indicated cytokines from epidermal or dermal cell suspensions was
performed as previously described (Mabuchi et al., 2011).
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Statistics
All quantitative data were shown as the mean±SEM unless otherwise
indicated. Simple comparisons of means and SEM of data were made
by using Student’s t-test (two-sided) and post hoc multiple compar-
isons were made by using Tukey’s test.
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